Socially Responsible Investment

Corporate Social Responsibility (CSR) is an integral part of Sanofi’s core business strategy. By building a pragmatic and innovative approach to meet today’s CSR challenges, it contributes to value creation and improving our business.

The Corporate Social Responsibility department, in coordination with the Investor Relations department, is in charge of the information analyzed by socially responsible investors and rating agencies which assess companies according to social, environmental, economic and governance criteria.

Sanofi CSR strategy is driven by material issues defined with the input of our stakeholders

The material issues, type of issue and boundaries

CSR Strategy embedded in the Business

Sanofi’s contribution goes beyond medical care. Whether improving access to care, reducing our environmental footprint, or taking on the role of a responsible corporate citizen in other ways, we want to make sure that Corporate Social Responsibility is embedded into all of our activities. 

Our reporting principles are based on the Global Reporting Initiative (GRI) standards, under the “Core” option. Sanofi is also a signatory of the United Nations Global Compact.

  • Sanofi publishes an Integrated Report based on the International Integrated Reporting Council (IIRC) framework. It presents, in a synthetic manner, the Group’s strategy for creating short, mid- and long-term value (financial and extra-financial) for the company and its stakeholders.
  • Sanofi also publishes in its French registration document (Document d’Enregistrement Universel) a chapter on Corporate Social Responsibility (Chapter 4) which includes our Statement of Extra Financial Performance (DPEF). An English translation of this chapter is available below.
  • CSR indicators and the auditors’ report are reported in the factsheet CSR Indicators Table and Auditor’s Report, see below.
  • Other reference documents and factsheets are available in the Document Center of the “Our Responsibility” section (see below).

Quick links

integrated report 2019

2019 Integrated Report

Chapter 4 of the 2017 Document de référence

Chapter 4 of the 2019 Document d'enregistrement universel

Woman and smartphone

Document center

our value creation

Our value creation

Our contribution to the UN SDG

Recognition for our extra-financial performance

Sanofi’s performance is recognized through our inclusion in the most important international Socially Responsible Investment (SRI) indices including:

  • Dow Jones Sustainability Index (DJSI) World (Bronze Class): reference index in sustainable Development
  • FTSE4Good (Financial Times Stock Exchange)
  • Access to Medicine Index (ATM)
  • Stoxx® Global ESG Leaders indices

Extra-financial performance

SANOFI rankings & scores - 2018/2019
Logo DJSI

DJSI 
Included in 2019 DJSI World for the 13th consecutive year

Included in the DJSI Europe


Score 82/100
3rd among
61 pharmaceuticals companies

Logo MSCI MSCI


Score: A
(Scale from CCC to AAA)
3rd among the 5 largest
pharmaceutical companies

Logo Sustainalytics Sustainalytics
(2018)


Score 71/100
4th among
160 pharmaceutical companies

Logo corporate knights

Global 100
Clean 200


28th among 100
(2)

22nd among 200
(all industry sectors)

Logo ISS ESG
ISS-ESG(3)


Score: B
(Scale from D- to A+)

Sanofi among top
3 pharmaceuticals leaders

Logo FTSE4Good FTSE4Good Score: 4,4/5
CDP Logo
CDP Climate Change
Score: B
CDP Water Score: A-
Logo ATM Index ATM index (2018)


7th among
20 pharmaceutical companies


(2)
Sanofi ranks 1st in pharmaceutical sector
(3)
ISS ESG acquired Oekom rating agency in 2018

Contacts

Sanofi Investor Relations
Yvonne Naughton

Tel: +33 (0)1 53 77 45 45
e-mail: ir@sanofi.com

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK